© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 26, 2018
The recently approved phenylketonuria (PKU) drug, pegvaliase, is helping patients experience less disease burden—and drastically in some cases.
October 11, 2018
Palynziq is specifically intended for use by patients with PKU over the age of 18 who have blood Phe levels at or above 600 μmol/L while following their current therapies.
July 10, 2018
Several promising new treatment developments are offering a ray of hope to Huntington’s patients, their at-risk children, and the clinicians who treat them.
Greater Baseline Retinal Nonperfusion Linked to Worsening Diabetic Retinopathy
John J. Miller, MD: A New Era For Psychiatric Medications
Aluminum Exposure Induces Cytokine Secretion in Crohn’s Disease Colons